Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study
Open accessThe DOI matches its Crossref record; 85 of the 86 references it cites were found in a registry or an index.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD), the most common liver disease, is closely associated with metabolic conditions such as obesity and diabetes mellitus, which significantly impact human health outcomes. The impaired lipid profiles observed in NAFLD individuals can further contribute to cardiovascular events. Despite the high prevalence of NAFLD, there is currently no confirmed intervention approved for its treatment. This study aimed to summarize the results of meta-analysis studies of randomized control trials assessing the impact of gut microbial therapy (probiotics, synbiotics, and prebiotics) on the lipid profile of individuals with NAFLD. Methods: A systematic search was conducted on PubMed, Scopus, Web of Science, and Cochrane Library up to November 1, 2022. Meta-analyses surveying the impact of microbial therapy on lipid profile parameters (triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and total cholesterol (TC)) in the NAFLD population were included in our umbrella review. The final effect size (ES) was estimated, and sensitivity and subgroup analyses were performed to explore heterogeneity. Results: Fifteen studies were included in this umbrella review. Microbial therapy significantly reduced TG (ES − 0.31, 95% CI − 0.51, − 0.11, P < 0.01), TC (ES − 1.04, 95% CI − 1.46, − 0.61, P < 0.01), and LDL (ES − 0.77, 95% CI − 1.15, − 0.39, P < 0.01) in individuals with NAFLD. However, the effect on HDL was not statistically significant (ES − 0.06; 95% CI − 0.19, 0.07, P = 0.39). Conclusion: Considering the absence of approved treatments for NAFLD and the promising role of microbial therapies in improving the three lipid profiles components in individuals with NAFLD, the use of these agents as alternative treatment options could be recommended. The findings underscore the potential of gut microbial therapy, including probiotics, synbiotics, and prebiotics, in managing NAFLD and its associated metabolic complications. Trial registration: PROSPERO (CRD42022346998). Graphical Abstract:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Gut microbial therapy by administration of probiotics, synbiotics and prebiotics may alleviate the medical condition in specific disorders, for example reduction of C-reactive protein50, low-density lipoprotein (LDL)51, alanine aminotransferase and aspartate aminotransferase52 and insulin resistance53 among non-alcoholic fatty liver disease (NAFLD).”
From Association between attention-deficit/hyperactivity disorders and intestinal disorders: A systematic review and Meta-analysis (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 1×
“The publication bias was assessed by visual inspection of the funnel plot and Egger regression test, and P value 0.1 was determined as the level of significance [41, 42].”
MethodInfluentialThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“The reporting of the results was based on Preferred Reporting Items for Systematic Reviews and Meta-Analy-ses (PRISMA) guidelines [39].”
MethodShea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636
Sterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“The publication bias was assessed by visual inspection of the funnel plot and Egger regression test, and P value 0.1 was determined as the level of significance [41, 42].”
MethodInfluentialGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 1×
“In addition to the relationship between NAFLD and other health conditions, this disease caused a significant burden globally [24–26].”
BackgroundThe Human Intestinal Microbiome in Health and Disease
Lynch, S. V., & Pedersen, O. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1600266 · Cited by 3,637 · cited 1×
“microbiota and are helpful for individuals’ health [30].”
BackgroundBile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829 · cited 1×
“A significant part of bile salt in the intestinal lumen is reabsorbed through the enterohepatic cycle, but 400 to 800 mg of bile salt will remain in the intestinal lumen, which can be deconjugated by gut microbiota [69, 70].”
BackgroundObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications
Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., Seifan, M., Mohkam, M., Masoumi, S., Berenjian, A., & Ghasemi, Y. (2019) · Foods · doi:10.3390/foods8030092 · Cited by 1,716
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577 · cited 1×
“Cholesterol particles of the medium are absorbed via Niemann–Pick C1 like 1 (NPC1L1) that are transporters located on intestinal cells membrane [80, 81].”
Background
Research works printed but not linked: 4
- Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009;13(1):9–19.
- Meroni M, Longo M, Dongiovanni P. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients. 2019;11(11). https://doi.org/10.3390/nu11112642. · DOI · Paper page
- Koutnikova H, Genser B, Monteiro-Sepulveda M, et al. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019;9(3):e017995. https://doi.org/10.1136/bmjopen-2017-017995. · DOI · Paper page
- Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2019;2019:1484598. https://doi.org/10.1155/2019/1484598. · DOI · Paper page
Cited by
Amini-Salehi, E., Letafatkar, N., Norouzi, N., Joukar, F., Habibi, A., Javid, M., Sattari, N., Khorasani, M., Farahmand, A., Tavakoli, S., et al. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103043 · Cited by 171
Self-citationSaeed, H., Díaz, L. A., Gil‐Gómez, A., Burton, J. P., Bajaj, J. S., Romero‐Gómez, M., Arrese, M. A., Arab, J. P., & Khan, M. Q. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0811 · Cited by 91
“Another meta-analysis revealed improved lipid profiles (reduced triglycerides, total cholesterol and LDL), in agreement with a previous one that included 22 RCTs (total 1301 patients) 76,77 .”
Vakilpour, A., Amini‐Salehi, E., Moghadam, A. S., Keivanlou, M., Letafatkar, N., Habibi, A., Hashemi, M., Eslami, N., Zare, R., Norouzi, N., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00281-7 · Cited by 35
Self-citationMicrobiota Transplant and Gynecological Disorders: The Bridge between Present and Future Treatments
Martinelli, S., Nannini, G., Cianchi, F., Staderini, F., Coratti, F., & Amedei, A. (2023) · Microorganisms · doi:10.3390/microorganisms11102407 · Cited by 35
“It has been demonstrated that many chronic conditions, such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD), are all linked to GM dysbiosis [9].”
BackgroundHashemi, S. M. H., Kheirandish, M., Rafati, S., Ghazalgoo, A., Amini‐Salehi, E., Keivanlou, M., Abbaszadeh, S., Saberian, P., & Rahimi, A. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02378-5 · Cited by 29
Self-citation
Metadata
- Authors
- Naghipour, A., Amini-Salehi, E., Orang Gorabzarmakhi, M., Shahdkar, M., Fouladi, B., Alipourfard, I., & Sanat, Z. M.
- Affiliations
- Kerman University of Medical Sciences (IR)
- Guilan University of Medical Sciences (IR)
- Zabol University of Medical Sciences (IR)
- Institute of Physical Chemistry (PL)
- Digestive Disease Research Institute (IR)
- Corresponding author
- Sanat, Zahra Momayez
- Venue
- Systematic Reviews
- Published
- 2023-08-21
- Volume
- 12
- Issue
- 1
- Pages
- 144-144
- ISSN
- 2046-4053 (ISSN-L)
- PMC
- PMC10441764
- OpenAlex
- W4386033594
- Cited by
- 37
- References
- 86
- Citations by year
- 2026: 3 · 2025: 18 · 2024: 13 · 2023: 3
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Systematic Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- non-alcoholic fatty liver disease, probiotics, synbiotics, prebiotics, lipid profile, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, dyslipidemia, obesity, diabetes mellitus, cardiovascular risk, metabolic complications, complementary and alternative medicine, gut microbiota modulation, dysbiosis
- MeSH terms
- Gastrointestinal Microbiome, Humans, Lipoproteins, HDL, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Probiotics, Prebiotics, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. https://app.cochat.ai/papers/10.1186/s13643-023-02299-x
- The paper
- Naghipour, A., Amini-Salehi, E., Orang Gorabzarmakhi, M., Shahdkar, M., Fouladi, B., Alipourfard, I., & Sanat, Z. M. (2023). Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study. Systematic Reviews. https://doi.org/10.1186/s13643-023-02299-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.